Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

AbbVie Inc. (NYSE:ABBV) saw its stock jump 3.4% after announcing a major licensing agreement with IGI Therapeutics, securing ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

Ichnos Glenmark Innovation & AbbVie ink exclusive global licensing agreement for ISB 2001: New York Saturday, July 12, 2025, 12:00 Hrs [IST] IGI Therapeutics SA, a wholly owned su ...

AbbVie has entered into a $700 million licensing agreement with IGI Therapeutics to co-develop ISB 2001, a promising ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

Glenmark shares hit record high after $2 billion AbbVie deal for cancer drug ISB 2001; analysts see it as a major biotech ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...